Literature DB >> 11120512

21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study.

C Moran1, R Azziz, E Carmina, D Dewailly, F Fruzzetti, L Ibañez, E S Knochenhauer, J A Marcondes, B B Mendonca, D Pignatelli, M Pugeat, V Rohmer, P W Speiser, S F Witchel.   

Abstract

OBJECTIVE: Our aim was to determine whether the clinical features of 21-hydroxylase-deficient nonclassic adrenal hyperplasia are correlated with either age at symptom onset or age at presentation, or both, and with the degree of adrenocortical abnormality. STUDY
DESIGN: In a multicenter cohort design 220 women with nonclassic adrenal hyperplasia, with a basal or adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone level >30.3 nmol/L, were studied, either prospectively (n = 39) or retrospectively (n = 181). Patients were stratified by age of presentation into 5 groups: (1) <10 years (n = 25), (2) 10 to 19 years (n = 64), (3) 20 to 29 years (n = 83), (4) 30 to 39 years (n = 30), and (5) 40 to 49 years (n = 16). Two patients >50 years old were excluded from the analysis because of age.
RESULTS: Ninety-two percent of patients <10 years old had premature pubarche at presentation, whereas clitoromegaly and acne were each present in only 20% of these younger subjects. With only patients > or =10 years old considered, presenting clinical features included hirsutism (59%), oligomenorrhea (54%), acne (33%), infertility (13%), clitoromegaly (10%), alopecia (8%), primary amenorrhea (4%), and premature pubarche (4%). Among the patients >/=10 years old, the prevalence but not the degree of hirsutism increased significantly with age. Basal levels of 17-hydroxyprogesterone in adolescents were significantly higher than the levels found either in children (<10 years old) or women 40 to 49 years old (P <.01 and P <.03, respectively), although no difference was noted in the stimulated 17-hydroxyprogesterone levels between age groups. The adrenocorticotropic hormone-stimulated levels but not the basal levels of 17-hydroxyprogesterone were significantly higher in patients with clitoromegaly than in women without clitoromegaly. Alternatively, there were no differences in either basal or stimulated 17-hydroxyprogesterone levels between patients with and those without hirsutism, acne, or alopecia.
CONCLUSION: In children <10 years old the most common presenting complaint was premature pubarche, whereas hirsutism and oligomenorrhea were more common in older patients. The prevalence of hirsutism increased with age, suggesting the progressive nature of nonclassic adrenal hyperplasia. Furthermore, the adrenocorticotropic hormone-stimulated levels of 17-hydroxyprogesterone were higher in patients with clitoromegaly, which suggests that the degree of adrenocortical dysfunction in nonclassic adrenal hyperplasia determines, at least in part, the clinical presentation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120512     DOI: 10.1067/mob.2000.108020

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  33 in total

1.  Clinical manifestations and hormonal profile of two women with Cushing's disease and mild deficiency of 21-hydroxylase.

Authors:  M Boronat; A Carrillo; A Ojeda; J Estrada; B Ezquieta; F Marín; F J Nóvoa
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 2.  Defects of steroidogenesis.

Authors:  A Biason-Lauber; M Boscaro; F Mantero; G Balercia
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

Review 3.  The way toward adulthood for females with nonclassic congenital adrenal hyperplasia.

Authors:  Georgia Ntali; Sokratis Charisis; Christo F Kylafi; Evangelia Vogiatzi; Lina Michala
Journal:  Endocrine       Date:  2021-04-14       Impact factor: 3.633

4.  Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families.

Authors:  Radha Nandagopal; Ninet Sinaii; Nilo A Avila; Carol Van Ryzin; Wuyan Chen; Gabriela P Finkielstain; Sneha P Mehta; Nazli B McDonnell; Deborah P Merke
Journal:  Eur J Endocrinol       Date:  2011-03-28       Impact factor: 6.664

Review 5.  Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update.

Authors:  Christine M Trapp; Sharon E Oberfield
Journal:  Steroids       Date:  2011-12-13       Impact factor: 2.668

6.  Genetic defects of the CYP21A2 gene in girls with premature adrenarche.

Authors:  N Skordis; C Shammas; A A P Phedonos; A Kyriakou; M Toumba; V Neocleous; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2014-12-07       Impact factor: 4.256

7.  An 88-year-old woman diagnosed with adrenal tumor and congenital adrenal hyperplasia: connection or coincidence?

Authors:  H Falhammar; M Thorén
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

8.  Nonclassic congenital adrenal hyperplasia.

Authors:  Selma Feldman Witchel; Ricardo Azziz
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-30

Review 9.  Nonclassic adrenal hyperplasia.

Authors:  Phyllis W Speiser
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

Review 10.  Biochemical and genetic diagnosis of 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Anna Wedell; Anna Nordenström
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.